WHICH IS YOUR CHOICE? NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL (AC-T) IN LOCALLY ADVANCED BREAST CANCER

被引：0
|
作者：
Kang, S. Y. [1 ]
Choi, J. -H. [1 ]
Lee, H. W. [1 ]
Ahn, M. [1 ]
Kim, K. S. [2 ]
机构：
[1] Ajou Univ, Sch Med, Dept Hematol Oncol, Suwon 441749, South Korea
[2] Ajou Univ, Sch Med, Dept Surg, Suwon 441749, South Korea
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：127 / 127
页数：1
相关论文
共 50 条
  • [1] WHICH IS YOUR CHOICE?; NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL(AC-T) IN LOCALLY ADVANCED BREAST CANCER
    Kang, S. Y.
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 135 - 135
  • [2] Which is your choice? Neoadjuvant doxorubicin hydrochloride and doxetaxel (AD) versus doxorubicin hydrochloride, cyclophosphamide, and paclitaxel (AC-T) in locally advanced breast cancer
    Kang, Seok Yun
    Choi, Jin-Hyuk
    Kim, Ku Sang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] WHICH IS YOUR CHOICE? NEOADJUVANT DOXORUBICIN AND DOXETAXEL (AD) VERSUS DOXORUBICIN, CYCLOPHOSPHAMIDE AND PACLITAXEL (ACT) IN LOCALLY ADVANCED BREAST CANCER
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [4] Comparison of Efficiency and Side Effect of Adriamycin and Doxetaxel and Adriamycin, Cyclophosphamide and Paclitaxel in Patients with Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
    Hong, W.
    Kim, K.
    Jung, Y.
    Kim, J.
    Kang, S.
    Chun, J.
    Chun, M.
    Yim, H.
    Kang, D.
    Kim, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S172 - S173
  • [5] Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
    Hong, Woo Sung
    Jeon, Ja Young
    Kang, Seok Yun
    Jung, Yong Sik
    Kim, Ji Young
    Ahn, Mi Sun
    Kang, Doo Kyoung
    Kim, Tae Hee
    Yim, Hyun Ee
    An, Young-Sil
    Park, Rae Woong
    Kim, Ku Sang
    [J]. JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2013, 85 (01): : 7 - 14
  • [6] Dose-dense taxotere (T) and adriamycin/cyclophosphamide (AC) as neoadjuvant treatment in locally advanced breast cancer (LABC).
    García-Mata, J
    Calvo, L
    García-Palomo, A
    Mel, JR
    Almanza, MC
    Ramos, M
    de Paz, LH
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S226 - S227
  • [7] Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
    Daniel Mendoza-Posada
    Teresa Vela-Chavez
    Enrique Bargallo-Rocha
    Nestor Villafañe
    Carlos Gamboa-Vignole
    Claudia Arce
    [J]. BMC Cancer, 7 (Suppl 1)
  • [8] The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
    Javan-Noughabi, Javad
    Rezapour, Aziz
    Kassani, Aziz
    Hatam, Nahid
    Ahmadloo, Niloofar
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2018, 23
  • [9] Efficacy and safety profile of the adriamycin/cyclophosphamide (AC) followed by docetaxel/cisplatin (DC) in locally advanced breast cancer
    Abdelhamid, T.
    Saber, M.
    Gaber, A. Abdel-Samie
    Selim, M.
    Youssef, O.
    Salama, A.
    Eldin, N. Aly
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Adriamycin & cyclophosphamide (AC) followed by docetaxel (D) versus AC followed by paclitaxel (P) in operable node positive breast cancer
    Abdel-Halim, I.
    Ei-Sadda, W.
    [J]. BREAST, 2011, 20 : S65 - S65
12345